Loading the company…
Loading the company…
Families: Peripheral nerve stimulation & intrathecal pumps.
All companies · Product and company coverage
In the last ten years FDA made 33 decisions for Infusyn Therapeutics (510(k) clearances, De Novo grants, PMA approvals and supplements) under the product codes MedaRep maps to 1 procedure family, the most in 2019 (9). The latest was on 2025-06-18.
| Family | Decisions on record |
|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 64 |
| Date | Kind | Number | Device |
|---|---|---|---|
| 2025-06-18 | PMA | P080012-S075 | PROMETRA PROGRAMMABLE INFUSION PUMP SYSTEM · Postapproval Study Protocol |
| 2024-12-12 | PMA | P080012-S074 | Prometra Programmable Infusion Pump System · Change Design/Components/Specifications/Material |
| 2024-08-09 | PMA | P080012-S073 | Prometra Programmable Infusion Pump System · Process Change - Manufacturer/Sterilizer/Packager/Supplier |
| 2022-07-12 | PMA | P080012-S070 | Prometra Programmable Infusion Pump System · Postapproval Study Protocol |
| 2022-04-28 | PMA | P080012-S072 | Prometra Programmable Infusion Pump System · Labeling Change - Indications/instructions/shelf life/tradename |
Decisions under the product codes mapped to the procedure families; devices filed under other codes are not here. Applicants are rolled up to Infusyn Therapeutics.